NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia

Published:2021-01-06 Issue:3 Volume:39 Page:736-746
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Scopim-Ribeiro Renata,Machado-Neto João Agostinho,Eide Christopher A.,Coelho-Silva Juan Luiz,Fenerich Bruna Alves,Fernandes Jaqueline Cristina,Scheucher Priscila Santos,Savage Stevens Samantha L.,de Melo Campos Paula,Olalla Saad Sara T.,de Carvalho Palma Leonardo,de Figueiredo-Pontes Lorena Lobo,Simões Belinda Pinto,Rego Eduardo Magalhães,Tognon Cristina E.,Druker Brian J.,Traina Fabiola

Funder

Fundação de Amparo à Pesquisa do Estado de São Paulo

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-020-01028-8.pdf

Reference31 articles.

1. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356

2. O’Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242–2249

3. Hughes TP, Saglio G, Quintas-Cardama A, Mauro MJ, Kim DW, Lipton JH, Bradley-Garelik MB, Ukropec J, Hochhaus A (2015) BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia 29:1832–1838

4. Apperley JF (2015) Chronic myeloid leukaemia. Lancet 385:1447–1459

5. Wang LM, Myers MG Jr, Sun XJ, Aaronson SA, White M, Pierce JH (1993) IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. Science 261:1591–1594

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NT157 as an Anticancer Drug Candidate That Targets Kinase- and Phosphatase-Mediated Signaling;Kinases and Phosphatases;2024-05-29

2. NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma;Hematology, Transfusion and Cell Therapy;2024-03

3. ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation;npj Breast Cancer;2023-11-30

4. Repressing IRS1/2 by NT157 inhibits the malignant behaviors of ovarian cancer through inactivating PI3K/AKT/mTOR pathway and inducing autophagy;The Kaohsiung Journal of Medical Sciences;2023-02-02

5. Drugging IGF-1R in cancer: New insights and emerging opportunities;Genes & Diseases;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3